The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)

Salah Ghabri, Erwan Autin, Anne-Isabelle Poullié and Jean Michel Josselin ()
Additional contact information
Salah Ghabri: HAS - Haute Autorité de Santé [Saint-Denis La Plaine]
Erwan Autin: HAS - Haute Autorité de Santé [Saint-Denis La Plaine]
Anne-Isabelle Poullié: HAS - Haute Autorité de Santé [Saint-Denis La Plaine]
Jean Michel Josselin: CREM - Centre de recherche en économie et management - UNICAEN - Université de Caen Normandie - NU - Normandie Université - UR - Université de Rennes - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Abstract: Background - Budget impact analysis (BIA) provides short- and medium-term estimates on changes in budgets and health outcomes resulting from the adoption of new health interventions. Objective - The purpose of this study is to present the newly developed French National Authority for Health (HAS) guidelines on budget impact analysis as follows: process, literature review, recommendations and comparisons with other guidelines. Methods - The development process of the HAS guidelines included a literature review (search dates: January 2000 to June 2016), a retrospective investigation of BIA previously submitted to HAS, a public consultation, international expert reviews and approval from the HAS Board and the Economic and Public Health Evaluation Committee of HAS. Results - Documents identified in the literature review included 12 national guidelines, 5 recommendations for good practices developed by national and international society of health economics and 14 methodological publications including recommendations for conducting BIA. Based on its research findings, HAS developed its first BIA guidelines, which include recommendations on the following topics: BIA definition, perspective, populations, time horizon, compared scenarios, budget impact models, costing, discounting, choice of clinical data, reporting of results and uncertainty exploration. Conclusion - It is expected that the HAS BIA guidelines will enhance the usefulness, quality and transparency of BIA submitted by drug manufacturers to HAS. BIA is becoming an essential part of a comprehensive economic assessment of healthcare interventions in France, which also includes cost-effectiveness analysis and equity of access to healthcare.

Keywords: budget impact analysis; methodological guidelines; health expenditure; health interventions; French Authority for Health; France; dépenses de santé; guide méthodologique; analyse d’impact budgétaire; interventions de santé; Haute Autorité de santé; France (search for similar items in EconPapers)
Date: 2018-04
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Published in PharmacoEconomics, 2018, 36 (4), pp.407-417. ⟨10.1007/s40273-017-0602-5⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-01683827

DOI: 10.1007/s40273-017-0602-5

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().